<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

	<channel><title><![CDATA[Latest Publisher Reports]]></title><atom:link href="http://www.researchmoz.com/publisher" rel="self" type="application/rss+xml" />
	<link>http://www.researchmoz.com</link>
	<description><![CDATA[Latest Publisher Reports]]></description>
	<lastBuildDate>Wed, 18 Jul 2012 12:20:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator><item><title>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contr <br><br>Original Post <a href=http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contr <br><br>Original Post <a href=http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Antibody Partnering Terms and Agreements</title><link>http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
&nbsp;


Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies


Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insigh <br><br>Original Post <a href=http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html>Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
&nbsp;


Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies


Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insigh <br><br>Original Post <a href=http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html>Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/antibody-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cancer Monoclonal Antibody Partnering Terms and Agreements</title><link>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value


The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody techn <br><br>Original Post <a href=http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html>Cancer Monoclonal Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value


The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody techn <br><br>Original Post <a href=http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html>Cancer Monoclonal Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cancer Vaccine Partnering Terms and Agreements</title><link>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html</link><comments>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html</guid><description><![CDATA[

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value


&nbsp;
The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercializa <br><br>Original Post <a href=http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html>Cancer Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value


&nbsp;
The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercializa <br><br>Original Post <a href=http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html>Cancer Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are <br><br>Original Post <a href=http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are <br><br>Original Post <a href=http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Antibiotics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value


The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commerci <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html>Antibiotics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value


The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commerci <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html>Antibiotics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies&nbsp;

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical  <br><br>Original Post <a href=http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies&nbsp;

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical  <br><br>Original Post <a href=http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Companion Diagnostics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 04 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[



The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the de <br><br>Original Post <a href=http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html>Companion Diagnostics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[



The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the de <br><br>Original Post <a href=http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html>Companion Diagnostics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/companion-diagnostics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html</link><comments>http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html#comments</comments><pubDate>Thu, 04 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html</guid><description><![CDATA[

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggere <br><br>Original Post <a href=http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html>Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggere <br><br>Original Post <a href=http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html>Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/clinical-stage-partnering-terms-and-agreements-in-pharma-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pharmacogenomics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 04 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Pharmacogenomic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomic technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are trigg <br><br>Original Post <a href=http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html>Pharmacogenomics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Pharmacogenomic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomic technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are trigg <br><br>Original Post <a href=http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html>Pharmacogenomics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmacogenomics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Personalized Medicine Partnering Terms and Agreements</title><link>http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Mon, 01 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html</guid><description><![CDATA[Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in t <br><br>Original Post <a href=http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html>Personalized Medicine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in t <br><br>Original Post <a href=http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html>Personalized Medicine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/personalized-medicine-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Biomarker Partnering Terms and Agreements</title><link>http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sat, 30 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html</guid><description><![CDATA[



The Biomarker Partnering Terms &amp; Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers


The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering dea <br><br>Original Post <a href=http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html>Biomarker Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[



The Biomarker Partnering Terms &amp; Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in biomarker partnering deals
Biomarker partnering agreement structure
Biomarker partnering contract documents
Top biomarker deals by value
Most active biomarker dealmakers


The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering dea <br><br>Original Post <a href=http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html>Biomarker Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biomarker-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bioinformatics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 07 Mar 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting  <br><br>Original Post <a href=http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html>Bioinformatics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in bioinformatics partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for bioinformatics

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting  <br><br>Original Post <a href=http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html>Bioinformatics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bioinformatics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Orphan Drugs Partnering Terms and Agreements</title><link>http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 28 Feb 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in orphan drugs partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan drugs partnering contract documents
Top orphan drugs deals by value


The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outc <br><br>Original Post <a href=http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html>Orphan Drugs Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in orphan drugs partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan drugs partnering contract documents
Top orphan drugs deals by value


The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outc <br><br>Original Post <a href=http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html>Orphan Drugs Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/orphan-drugs-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Partnering Deals and Alliances with Big Pharma</title><link>http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html</link><comments>http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html#comments</comments><pubDate>Thu, 28 Feb 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html</guid><description><![CDATA[
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:



Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company&rsquo;s dealmaking activity since 2005, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2005 &ndash; number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together <br><br>Original Post <a href=http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html>Partnering Deals and Alliances with Big Pharma</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:



Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company&rsquo;s dealmaking activity since 2005, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2005 &ndash; number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together <br><br>Original Post <a href=http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html>Partnering Deals and Alliances with Big Pharma</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/partnering-deals-and-alliances-with-big-pharma-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Regenerative Medicine and Stem Cells Partnering Terms and Agreements</title><link>http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Fri, 08 Feb 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html</guid><description><![CDATA[Description

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in regenerative medicine and stem cells deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells


The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

This report provides det <br><br>Original Post <a href=http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html>Regenerative Medicine and Stem Cells Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Description

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in regenerative medicine and stem cells deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for regenerative medicine and stem cells


The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

This report provides det <br><br>Original Post <a href=http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html>Regenerative Medicine and Stem Cells Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acne Partnering 2007 - 2013</title><link>http://www.researchmoz.com/acne-partnering-2007-2013-report.html</link><comments>http://www.researchmoz.com/acne-partnering-2007-2013-report.html#comments</comments><pubDate>Thu, 31 Jan 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acne-partnering-2007-2013-report.html</guid><description><![CDATA[Provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies&nbsp;

Acne Partnering 2007-2013 report provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in acne partnering deals
Top acne deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type


Acne Partnering 2007-2013 provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an analysis of acne partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors acne technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of <br><br>Original Post <a href=http://www.researchmoz.com/acne-partnering-2007-2013-report.html>Acne Partnering 2007 - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies&nbsp;

Acne Partnering 2007-2013 report provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in acne partnering deals
Top acne deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type


Acne Partnering 2007-2013 provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an analysis of acne partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors acne technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;
Understanding the flexibility of <br><br>Original Post <a href=http://www.researchmoz.com/acne-partnering-2007-2013-report.html>Acne Partnering 2007 - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acne-partnering-2007-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccine Partnering Terms and Agreements</title><link>http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Fri, 11 Jan 2013 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html</guid><description><![CDATA[



The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines


The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical in <br><br>Original Post <a href=http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html>Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[



The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.



Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines


The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical in <br><br>Original Post <a href=http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html>Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccine-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Drug Delivery Partnering Terms and Agreements</title><link>http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 15 Nov 2012 00:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are trigg <br><br>Original Post <a href=http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html>Drug Delivery Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.
&nbsp;

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are trigg <br><br>Original Post <a href=http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html>Drug Delivery Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/drug-delivery-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Infectives Vaccine Partnering Terms and Agreements</title><link>http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Thu, 01 Nov 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectives vaccine partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes. &nbsp;The report also includes adjuvant deals and alliances.&nbsp;

This report provides details of the latest infectives vaccine agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contract doc <br><br>Original Post <a href=http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html>Infectives Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectives vaccine partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes. &nbsp;The report also includes adjuvant deals and alliances.&nbsp;

This report provides details of the latest infectives vaccine agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contract doc <br><br>Original Post <a href=http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html>Infectives Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/infectives-vaccine-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Diagnostics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Mon, 01 Oct 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this  <br><br>Original Post <a href=http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html>Diagnostics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this  <br><br>Original Post <a href=http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html>Diagnostics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/diagnostics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Dermatology Partnering Terms and Agreements</title><link>http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Mon, 01 Oct 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors bacterials technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contract documents provide this insight where press releases a <br><br>Original Post <a href=http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html>Dermatology Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors bacterials technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contract documents provide this insight where press releases a <br><br>Original Post <a href=http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html>Dermatology Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/dermatology-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gynecology Partnering Terms and Agreements</title><link>http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sat, 01 Sep 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html</guid><description><![CDATA[The Gynecology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter gynecology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gynecology technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this in <br><br>Original Post <a href=http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html>Gynecology Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Gynecology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter gynecology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gynecology technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this in <br><br>Original Post <a href=http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html>Gynecology Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gynecology-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Respiratory Partnering Terms and Agreements</title><link>http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sat, 01 Sep 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html</guid><description><![CDATA[The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter respiratory partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors respiratory technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide thi <br><br>Original Post <a href=http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html>Respiratory Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter respiratory partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors respiratory technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide thi <br><br>Original Post <a href=http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html>Respiratory Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/respiratory-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pediatrics Partnering Terms and Agreements </title><link>http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sat, 01 Sep 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter pediatrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pediatrics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this in <br><br>Original Post <a href=http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html>Pediatrics Partnering Terms and Agreements </a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Pediatrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pediatrics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter pediatrics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pediatrics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this in <br><br>Original Post <a href=http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html>Pediatrics Partnering Terms and Agreements </a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pediatrics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Musculoskeletal Partnering Terms and Agreements </title><link>http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sat, 01 Sep 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html</guid><description><![CDATA[The Musculoskeletal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter musculoskeletal partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors musculoskeletal technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract docum <br><br>Original Post <a href=http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html>Musculoskeletal Partnering Terms and Agreements </a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Musculoskeletal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter musculoskeletal partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors musculoskeletal technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract docum <br><br>Original Post <a href=http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html>Musculoskeletal Partnering Terms and Agreements </a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/musculoskeletal-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Obstretics Partnering 2007-2012</title><link>http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html#comments</comments><pubDate>Sat, 01 Sep 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html</guid><description><![CDATA[Obstretics Partnering 2007-2012 report provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in obstretics partnering deals

Top obstretics deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Obstretics Partnering 2007-2012 provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of obstretics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstretics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you  <br><br>Original Post <a href=http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html>Obstretics Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Obstretics Partnering 2007-2012 report provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in obstretics partnering deals

Top obstretics deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Obstretics Partnering 2007-2012 provides understanding and access to the obstretics partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of obstretics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors obstretics technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you  <br><br>Original Post <a href=http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html>Obstretics Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/obstretics-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Infectives Partnering Terms and Agreements</title><link>http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Tue, 10 Jul 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in infectives partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Infectives partnering agreement structure
Infectives partnering contract documents
Top infectives deals by value
Most active infectives dealmakers


The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives techn <br><br>Original Post <a href=http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html>Infectives Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in infectives partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Infectives partnering agreement structure
Infectives partnering contract documents
Top infectives deals by value
Most active infectives dealmakers


The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives techn <br><br>Original Post <a href=http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html>Infectives Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/infectives-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Viral Partnering Terms and Agreements</title><link>http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Tue, 10 Jul 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in viral partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Viral partnering agreement structure
Viral partnering contract documents
Top viral deals by value
Most active viral dealmakers


The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting  <br><br>Original Post <a href=http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html>Viral Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in viral partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Viral partnering agreement structure
Viral partnering contract documents
Top viral deals by value
Most active viral dealmakers


The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting  <br><br>Original Post <a href=http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html>Viral Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/viral-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bacterial Partnering Terms and Agreements</title><link>http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Sun, 01 Jul 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html</guid><description><![CDATA[
The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in bacterial partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Bacterial partnering agreement structure
Bacterial partnering contract documents
Top bacterial deals by value
Most active bacterial dealmakers


The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. Thes <br><br>Original Post <a href=http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html>Bacterial Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.


Trends in bacterial partnering deals
Average deal terms for headline, upfront and royalty by stage of development
Bacterial partnering agreement structure
Bacterial partnering contract documents
Top bacterial deals by value
Most active bacterial dealmakers


The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. Thes <br><br>Original Post <a href=http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html>Bacterial Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bacterial-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Actelion Partnering 2005-2012</title><link>http://www.researchmoz.com/actelion-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/actelion-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/actelion-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Actelion and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/actelion-partnering-2005-2012-report.html>Actelion Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Actelion and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/actelion-partnering-2005-2012-report.html>Actelion Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/actelion-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Aspen Partnering 2005-2012</title><link>http://www.researchmoz.com/aspen-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/aspen-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/aspen-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Aspen and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/aspen-partnering-2005-2012-report.html>Aspen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Aspen and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/aspen-partnering-2005-2012-report.html>Aspen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/aspen-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Endo Partnering 2005-2012</title><link>http://www.researchmoz.com/endo-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/endo-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/endo-partnering-2005-2012-report.html</guid><description><![CDATA[iver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phas <br><br>Original Post <a href=http://www.researchmoz.com/endo-partnering-2005-2012-report.html>Endo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[iver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phas <br><br>Original Post <a href=http://www.researchmoz.com/endo-partnering-2005-2012-report.html>Endo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/endo-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Galderma Partnering 2005-2012</title><link>http://www.researchmoz.com/galderma-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/galderma-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/galderma-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Galderma and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/galderma-partnering-2005-2012-report.html>Galderma Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Galderma and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/galderma-partnering-2005-2012-report.html>Galderma Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/galderma-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Grifols Partnering 2005-2012</title><link>http://www.researchmoz.com/grifols-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/grifols-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/grifols-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/grifols-partnering-2005-2012-report.html>Grifols Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Grifols and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/grifols-partnering-2005-2012-report.html>Grifols Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/grifols-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Purdue Partnering 2005-2012</title><link>http://www.researchmoz.com/purdue-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/purdue-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/purdue-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Purdue and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/purdue-partnering-2005-2012-report.html>Purdue Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Purdue and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/purdue-partnering-2005-2012-report.html>Purdue Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/purdue-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Diabetes Partnering 2007-2012</title><link>http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html</guid><description><![CDATA[The Diabetes Partnering 2007-2012 provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of diabetes partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driven report contains over 500 links to online copies of actual <br><br>Original Post <a href=http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html>Diabetes Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Diabetes Partnering 2007-2012 provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of diabetes partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driven report contains over 500 links to online copies of actual <br><br>Original Post <a href=http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html>Diabetes Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/diabetes-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Liver Disease Partnering 2007-2012</title><link>http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html</guid><description><![CDATA[Liver Disease Partnering  2007-2012 provides understanding and access to the liver disease partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of liver disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 50 links to online cop <br><br>Original Post <a href=http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html>Liver Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Liver Disease Partnering  2007-2012 provides understanding and access to the liver disease partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of liver disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 50 links to online cop <br><br>Original Post <a href=http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html>Liver Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/liver-disease-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lysosomal Storage Disease Partnering 2007-2012</title><link>http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html</guid><description><![CDATA[Lysosomal Storage Disease Partnering  2007-2012 provides understanding and access to the lysosomal storage disease partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of lysosomal storage disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lysosomal storage disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data dr <br><br>Original Post <a href=http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html>Lysosomal Storage Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Lysosomal Storage Disease Partnering  2007-2012 provides understanding and access to the lysosomal storage disease partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of lysosomal storage disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lysosomal storage disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data dr <br><br>Original Post <a href=http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html>Lysosomal Storage Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lysosomal-storage-disease-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Nutrition and Vitamin Partnering 2007-2012</title><link>http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html</guid><description><![CDATA[Nutrition &amp; Vitamins Partnering 2007-2012 provides understanding and access to the nutrition &amp; vitamins partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of nutrition &amp; vitamins partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors nutrition &amp; vitamins technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driv <br><br>Original Post <a href=http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html>Nutrition and Vitamin Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Nutrition &amp; Vitamins Partnering 2007-2012 provides understanding and access to the nutrition &amp; vitamins partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of nutrition &amp; vitamins partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors nutrition &amp; vitamins technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driv <br><br>Original Post <a href=http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html>Nutrition and Vitamin Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/nutrition-and-vitamin-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Liver Cancer Partnering 2007-2012</title><link>http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html</guid><description><![CDATA[The Liver Cancer Partnering 2007-2012 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 25links to online copie <br><br>Original Post <a href=http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html>Liver Cancer Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Liver Cancer Partnering 2007-2012 provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 25links to online copie <br><br>Original Post <a href=http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html>Liver Cancer Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/liver-cancer-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anxiety Partnering 2007-2012</title><link>http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html</guid><description><![CDATA[The Anxiety Partnering  2007-2012 provides understanding and access to the anxiety partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of anxiety partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors anxiety technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 35 links to online copies of actual anxiet <br><br>Original Post <a href=http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html>Anxiety Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Anxiety Partnering  2007-2012 provides understanding and access to the anxiety partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of anxiety partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors anxiety technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 35 links to online copies of actual anxiet <br><br>Original Post <a href=http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html>Anxiety Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anxiety-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Attention Deficit Hyperactivity Disorder Partnering 2007-2012</title><link>http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html</guid><description><![CDATA[The Attention Deficit Disorder Partnering  2007-2012 provides understanding and access to the attention deficit disorder partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of attention deficit disorder partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors attention deficit disorder technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This <br><br>Original Post <a href=http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html>Attention Deficit Hyperactivity Disorder Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Attention Deficit Disorder Partnering  2007-2012 provides understanding and access to the attention deficit disorder partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of attention deficit disorder partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors attention deficit disorder technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This <br><br>Original Post <a href=http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html>Attention Deficit Hyperactivity Disorder Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/attention-deficit-hyperactivity-disorder-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Dementia Partnering 2007-2012</title><link>http://www.researchmoz.com/dementia-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/dementia-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/dementia-partnering-2007-2012-report.html</guid><description><![CDATA[The Dementia Partnering  2007-2012 provides understanding and access to the dementia partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of dementia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dementia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 200 links to online copies of actual d <br><br>Original Post <a href=http://www.researchmoz.com/dementia-partnering-2007-2012-report.html>Dementia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Dementia Partnering  2007-2012 provides understanding and access to the dementia partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of dementia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dementia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 200 links to online copies of actual d <br><br>Original Post <a href=http://www.researchmoz.com/dementia-partnering-2007-2012-report.html>Dementia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/dementia-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Alzheimer&#039;s Disease Partnering 2007-2012</title><link>http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html</guid><description><![CDATA[The Alzheimers Disease Partnering  2007-2012 provides understanding and access to the alzheimers disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of alzheimers disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors alzheimers disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains ov <br><br>Original Post <a href=http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html>Alzheimer&#039;s Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Alzheimers Disease Partnering  2007-2012 provides understanding and access to the alzheimers disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of alzheimers disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors alzheimers disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains ov <br><br>Original Post <a href=http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html>Alzheimer&#039;s Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/alzheimers-disease-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Depression Partnering 2007-2012</title><link>http://www.researchmoz.com/depression-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/depression-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/depression-partnering-2007-2012-report.html</guid><description><![CDATA[The Depression Partnering  2007-2012 provides understanding and access to the depression partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of depression partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 70 links to online copies of  <br><br>Original Post <a href=http://www.researchmoz.com/depression-partnering-2007-2012-report.html>Depression Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Depression Partnering  2007-2012 provides understanding and access to the depression partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of depression partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 70 links to online copies of  <br><br>Original Post <a href=http://www.researchmoz.com/depression-partnering-2007-2012-report.html>Depression Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/depression-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Schizophrenia Partnering 2007-2012</title><link>http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html</guid><description><![CDATA[The Schizophrenia Partnering  2007-2012 provides understanding and access to the schizophrenia partnering deals and agreements entered into by the worlds leading healthcare companies  .The report provides an analysis of schizophrenia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 80 links to online  <br><br>Original Post <a href=http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html>Schizophrenia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Schizophrenia Partnering  2007-2012 provides understanding and access to the schizophrenia partnering deals and agreements entered into by the worlds leading healthcare companies  .The report provides an analysis of schizophrenia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 80 links to online  <br><br>Original Post <a href=http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html>Schizophrenia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/schizophrenia-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sleep disorders Partnering 2007-2012</title><link>http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html</guid><description><![CDATA[The Sleep Disorders Partnering  2007-2012 provides understanding and access to the sleep disorders partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of  sleep disorders partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 60 links to o <br><br>Original Post <a href=http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html>Sleep disorders Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Sleep Disorders Partnering  2007-2012 provides understanding and access to the sleep disorders partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of  sleep disorders partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 60 links to o <br><br>Original Post <a href=http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html>Sleep disorders Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sleep-disorders-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Epilepsy Partnering 2007-2012</title><link>http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html</guid><description><![CDATA[pective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 40 links to online copies of actual epilepsy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.The initial chapters of this report provide an orientation of epilepsy partnering trends.Chapter 1 provides an introduction to the report, whilst chapter 2 provides  <br><br>Original Post <a href=http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html>Epilepsy Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[pective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 40 links to online copies of actual epilepsy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.The initial chapters of this report provide an orientation of epilepsy partnering trends.Chapter 1 provides an introduction to the report, whilst chapter 2 provides  <br><br>Original Post <a href=http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html>Epilepsy Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/epilepsy-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Migraine Partnering 2007-2012</title><link>http://www.researchmoz.com/migraine-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/migraine-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/migraine-partnering-2007-2012-report.html</guid><description><![CDATA[The Migraine Partnering  2007-2012 provides understanding and access to the migraine partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of migraine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors migraine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 40 links to online copies of actual m <br><br>Original Post <a href=http://www.researchmoz.com/migraine-partnering-2007-2012-report.html>Migraine Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Migraine Partnering  2007-2012 provides understanding and access to the migraine partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of migraine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors migraine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 40 links to online copies of actual m <br><br>Original Post <a href=http://www.researchmoz.com/migraine-partnering-2007-2012-report.html>Migraine Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/migraine-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Motor Neurone Disease Partnering 2007-2012</title><link>http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html</guid><description><![CDATA[The Motor Neurone Disease Partnering  2007-2012 provides understanding and access to the motor neurone disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of motor neurone disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors migraine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains ove <br><br>Original Post <a href=http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html>Motor Neurone Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Motor Neurone Disease Partnering  2007-2012 provides understanding and access to the motor neurone disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of motor neurone disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors migraine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains ove <br><br>Original Post <a href=http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html>Motor Neurone Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/motor-neurone-disease-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Multiple Sclerosis Partnering 2007-2012</title><link>http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html</guid><description><![CDATA[The Multiple Sclerosis Partnering  2007-2012 provides understanding and access to the multiple sclerosis partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of multiple sclerosis disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple sclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report con <br><br>Original Post <a href=http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html>Multiple Sclerosis Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Multiple Sclerosis Partnering  2007-2012 provides understanding and access to the multiple sclerosis partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of multiple sclerosis disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple sclerosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report con <br><br>Original Post <a href=http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html>Multiple Sclerosis Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/multiple-sclerosis-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pain Partnering 2007-2012</title><link>http://www.researchmoz.com/pain-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/pain-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pain-partnering-2007-2012-report.html</guid><description><![CDATA[The Pain Partnering 2007-2012 provides understanding and access to the pain partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of pain disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pain technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driven report contains over 400 links to online copies of actual pain de <br><br>Original Post <a href=http://www.researchmoz.com/pain-partnering-2007-2012-report.html>Pain Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Pain Partnering 2007-2012 provides understanding and access to the pain partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of pain disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pain technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.This data driven report contains over 400 links to online copies of actual pain de <br><br>Original Post <a href=http://www.researchmoz.com/pain-partnering-2007-2012-report.html>Pain Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pain-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Neuralgia Partnering 2007-2012</title><link>http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html</guid><description><![CDATA[The Neuralgia Partnering  2007-2012 provides understanding and access to the neuralgia partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of neuralgia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuralgia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 30 links to online copies of actua <br><br>Original Post <a href=http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html>Neuralgia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Neuralgia Partnering  2007-2012 provides understanding and access to the neuralgia partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of neuralgia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuralgia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 30 links to online copies of actua <br><br>Original Post <a href=http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html>Neuralgia Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/neuralgia-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Parkinson&#039;s Disease Partnering 2007-2012</title><link>http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html</guid><description><![CDATA[The Parkinsons Disease Partnering  2007-2012 provides understanding and access to the Parkinsons disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of  Parkinsons disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Parkinsons disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains o <br><br>Original Post <a href=http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html>Parkinson&#039;s Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Parkinsons Disease Partnering  2007-2012 provides understanding and access to the Parkinsons disease partnering deals and agreements entered into by the worlds leading healthcare companies .The report provides an analysis of  Parkinsons disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Parkinsons disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains o <br><br>Original Post <a href=http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html>Parkinson&#039;s Disease Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/parkinsons-disease-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Spinal Cord Partnering 2007-2012</title><link>http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html</guid><description><![CDATA[The Spinal Cord Partnering  2007-2012 provides understanding and access to the spinal cord partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of spinal cord disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors spinal cord technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 70 links to online <br><br>Original Post <a href=http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html>Spinal Cord Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Spinal Cord Partnering  2007-2012 provides understanding and access to the spinal cord partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of spinal cord disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors spinal cord technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 70 links to online <br><br>Original Post <a href=http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html>Spinal Cord Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/spinal-cord-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Stroke Partnering 2007-2012</title><link>http://www.researchmoz.com/stroke-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/stroke-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/stroke-partnering-2007-2012-report.html</guid><description><![CDATA[The Stroke Partnering  2007-2012 provides understanding and access to the stroke partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of stroke partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors stroke technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 80 links to online copies of actual stroke dea <br><br>Original Post <a href=http://www.researchmoz.com/stroke-partnering-2007-2012-report.html>Stroke Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Stroke Partnering  2007-2012 provides understanding and access to the stroke partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of stroke partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors stroke technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven report contains over 80 links to online copies of actual stroke dea <br><br>Original Post <a href=http://www.researchmoz.com/stroke-partnering-2007-2012-report.html>Stroke Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/stroke-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Traumatic Brain Injury Partnering 2007-2012</title><link>http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html</link><comments>http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html</guid><description><![CDATA[The Traumatic Brain Injury Partnering  2007-2012 provides understanding and access to the traumatic brain injury partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of traumatic brain injury partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors traumatic brain injury technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven rep <br><br>Original Post <a href=http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html>Traumatic Brain Injury Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[The Traumatic Brain Injury Partnering  2007-2012 provides understanding and access to the traumatic brain injury partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides an analysis of traumatic brain injury partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors traumatic brain injury technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered  contract documents provide this insight where press releases do not.This data driven rep <br><br>Original Post <a href=http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html>Traumatic Brain Injury Partnering 2007-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/traumatic-brain-injury-partnering-2007-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Abbott Partnering 2005-2012</title><link>http://www.researchmoz.com/abbott-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/abbott-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/abbott-partnering-2005-2012-report.html</guid><description><![CDATA[s. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of <br><br>Original Post <a href=http://www.researchmoz.com/abbott-partnering-2005-2012-report.html>Abbott Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[s. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of <br><br>Original Post <a href=http://www.researchmoz.com/abbott-partnering-2005-2012-report.html>Abbott Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/abbott-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Actavis Partnering 2005-2012</title><link>http://www.researchmoz.com/actavis-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/actavis-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/actavis-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Actavis and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/actavis-partnering-2005-2012-report.html>Actavis Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Actavis and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/actavis-partnering-2005-2012-report.html>Actavis Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/actavis-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Alcon Partnering 2005-2012</title><link>http://www.researchmoz.com/alcon-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/alcon-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/alcon-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Alcon and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/alcon-partnering-2005-2012-report.html>Alcon Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Alcon and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/alcon-partnering-2005-2012-report.html>Alcon Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/alcon-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Allergan Partnering 2005-2012</title><link>http://www.researchmoz.com/allergan-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/allergan-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/allergan-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Allergan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/allergan-partnering-2005-2012-report.html>Allergan Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Allergan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/allergan-partnering-2005-2012-report.html>Allergan Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/allergan-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Amgen Partnering 2005-2012</title><link>http://www.researchmoz.com/amgen-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/amgen-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/amgen-partnering-2005-2012-report.html</guid><description><![CDATA[ficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering act <br><br>Original Post <a href=http://www.researchmoz.com/amgen-partnering-2005-2012-report.html>Amgen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[ficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering act <br><br>Original Post <a href=http://www.researchmoz.com/amgen-partnering-2005-2012-report.html>Amgen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/amgen-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Apotex Partnering 2005-2012</title><link>http://www.researchmoz.com/apotex-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/apotex-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/apotex-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Apotex and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/apotex-partnering-2005-2012-report.html>Apotex Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Apotex and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/apotex-partnering-2005-2012-report.html>Apotex Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/apotex-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Astellas Partnering 2005-2012</title><link>http://www.researchmoz.com/astellas-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/astellas-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/astellas-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Astellas and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/astellas-partnering-2005-2012-report.html>Astellas Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Astellas and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/astellas-partnering-2005-2012-report.html>Astellas Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/astellas-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AstraZeneca Partnering 2005-2012</title><link>http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand AstraZeneca and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading  <br><br>Original Post <a href=http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html>AstraZeneca Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand AstraZeneca and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading  <br><br>Original Post <a href=http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html>AstraZeneca Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/astrazeneca-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Baxter Partnering 2005-2012</title><link>http://www.researchmoz.com/baxter-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/baxter-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/baxter-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Baxter and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/baxter-partnering-2005-2012-report.html>Baxter Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Baxter and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/baxter-partnering-2005-2012-report.html>Baxter Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/baxter-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bayer Partnering 2005-2012</title><link>http://www.researchmoz.com/bayer-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/bayer-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bayer-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Bayer and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/bayer-partnering-2005-2012-report.html>Bayer Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Bayer and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/bayer-partnering-2005-2012-report.html>Bayer Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bayer-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Biogen Idec Partnering 2005-2012</title><link>http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Biogen Idec and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading  <br><br>Original Post <a href=http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html>Biogen Idec Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Biogen Idec and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading  <br><br>Original Post <a href=http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html>Biogen Idec Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biogen-idec-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Boehringer Ingelheim Partnering 2005-2012</title><link>http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Boehringer Ingelheim and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the <br><br>Original Post <a href=http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html>Boehringer Ingelheim Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Boehringer Ingelheim and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the <br><br>Original Post <a href=http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html>Boehringer Ingelheim Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/boehringer-ingelheim-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bristol-Myers Squibb Partnering 2005-2012</title><link>http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the <br><br>Original Post <a href=http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html>Bristol-Myers Squibb Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the <br><br>Original Post <a href=http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html>Bristol-Myers Squibb Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bristol-myers-squibb-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Celgene Partnering 2005-2012</title><link>http://www.researchmoz.com/celgene-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/celgene-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/celgene-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Celgene and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/celgene-partnering-2005-2012-report.html>Celgene Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Celgene and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/celgene-partnering-2005-2012-report.html>Celgene Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/celgene-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cephalon Partnering 2005-2012</title><link>http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html>Cephalon Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html>Cephalon Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cephalon-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Chugai Partnering 2005-2012</title><link>http://www.researchmoz.com/chugai-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/chugai-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/chugai-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Chugai and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/chugai-partnering-2005-2012-report.html>Chugai Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Chugai and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/chugai-partnering-2005-2012-report.html>Chugai Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/chugai-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CSL Partnering 2005-2012</title><link>http://www.researchmoz.com/csl-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/csl-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/csl-partnering-2005-2012-report.html</guid><description><![CDATA[terests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a  <br><br>Original Post <a href=http://www.researchmoz.com/csl-partnering-2005-2012-report.html>CSL Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[terests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a  <br><br>Original Post <a href=http://www.researchmoz.com/csl-partnering-2005-2012-report.html>CSL Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/csl-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Daiichi Sankyo Partnering 2005-2012</title><link>http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Daiichi Sankyo and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leadi <br><br>Original Post <a href=http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html>Daiichi Sankyo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Daiichi Sankyo and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leadi <br><br>Original Post <a href=http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html>Daiichi Sankyo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/daiichi-sankyo-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Dainippon Sumitomo Partnering 2005-2012</title><link>http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Dainippon Sumitomo and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the l <br><br>Original Post <a href=http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html>Dainippon Sumitomo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Dainippon Sumitomo and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the l <br><br>Original Post <a href=http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html>Dainippon Sumitomo Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/dainippon-sumitomo-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Eisai Partnering 2005-2012</title><link>http://www.researchmoz.com/eisai-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/eisai-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/eisai-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Eisai and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/eisai-partnering-2005-2012-report.html>Eisai Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Eisai and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/eisai-partnering-2005-2012-report.html>Eisai Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/eisai-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Eli Lilly Partnering 2005-2012</title><link>http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Eli Lilly and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading pa <br><br>Original Post <a href=http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html>Eli Lilly Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Eli Lilly and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading pa <br><br>Original Post <a href=http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html>Eli Lilly Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/eli-lilly-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Forest Partnering 2005-2012</title><link>http://www.researchmoz.com/forest-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/forest-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/forest-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Forest and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/forest-partnering-2005-2012-report.html>Forest Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Forest and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/forest-partnering-2005-2012-report.html>Forest Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/forest-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Genentech Partnering 2005-2012</title><link>http://www.researchmoz.com/genentech-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/genentech-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/genentech-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Genentech and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading pa <br><br>Original Post <a href=http://www.researchmoz.com/genentech-partnering-2005-2012-report.html>Genentech Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Genentech and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading pa <br><br>Original Post <a href=http://www.researchmoz.com/genentech-partnering-2005-2012-report.html>Genentech Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/genentech-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Genzyme Partnering 2005-2012</title><link>http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Genzyme and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html>Genzyme Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Genzyme and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html>Genzyme Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/genzyme-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gilead Sciences Partnering 2005-2012</title><link>http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html</guid><description><![CDATA[rests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a co <br><br>Original Post <a href=http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html>Gilead Sciences Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[rests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a co <br><br>Original Post <a href=http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html>Gilead Sciences Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gilead-sciences-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>GlaxoSmithKline Partnering 2005-2012</title><link>http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand GlaxoSmithKline and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the lead <br><br>Original Post <a href=http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html>GlaxoSmithKline Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand GlaxoSmithKline and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the lead <br><br>Original Post <a href=http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html>GlaxoSmithKline Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/glaxosmithkline-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hospira Partnering 2005-2012</title><link>http://www.researchmoz.com/hospira-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/hospira-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hospira-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Hospira and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/hospira-partnering-2005-2012-report.html>Hospira Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Hospira and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/hospira-partnering-2005-2012-report.html>Hospira Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hospira-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Johnson &amp; Johnson / Janssen Partnering 2005-2012</title><link>http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Johnson & Johnson and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the le <br><br>Original Post <a href=http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html>Johnson &amp; Johnson / Janssen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Johnson & Johnson and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the le <br><br>Original Post <a href=http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html>Johnson &amp; Johnson / Janssen Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/johnson-and-johnson-janssen-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Kyowa Hakko Partnering 2005-2012</title><link>http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Kyowa Hakko Kirin and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the l <br><br>Original Post <a href=http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html>Kyowa Hakko Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Kyowa Hakko Kirin and its partnering interests and activities over the past seven years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the l <br><br>Original Post <a href=http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html>Kyowa Hakko Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/kyowa-hakko-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lundbeck Partnering 2005-2012</title><link>http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Lundbeck and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html>Lundbeck Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Lundbeck and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html>Lundbeck Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lundbeck-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Menarini Partnering 2005-2012</title><link>http://www.researchmoz.com/menarini-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/menarini-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/menarini-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Menarini and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/menarini-partnering-2005-2012-report.html>Menarini Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Menarini and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/menarini-partnering-2005-2012-report.html>Menarini Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/menarini-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Merck &amp; Co Partnering 2005-2012</title><link>http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Merck & Co and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading p <br><br>Original Post <a href=http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html>Merck &amp; Co Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Merck & Co and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading p <br><br>Original Post <a href=http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html>Merck &amp; Co Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/merck-and-co-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Merck KGaA / Merck Serono Partnering 2005-2012</title><link>http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html</guid><description><![CDATA[ifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the su <br><br>Original Post <a href=http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html>Merck KGaA / Merck Serono Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[ifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the su <br><br>Original Post <a href=http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html>Merck KGaA / Merck Serono Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/merck-kgaa-merck-serono-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mitsubishi Tanabe Partnering 2005-2012</title><link>http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Mitsubishi Tanabe and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the le <br><br>Original Post <a href=http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html>Mitsubishi Tanabe Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Mitsubishi Tanabe and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the le <br><br>Original Post <a href=http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html>Mitsubishi Tanabe Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mitsubishi-tanabe-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mylan Partnering 2005-2012</title><link>http://www.researchmoz.com/mylan-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/mylan-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mylan-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Mylan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/mylan-partnering-2005-2012-report.html>Mylan Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Mylan and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partne <br><br>Original Post <a href=http://www.researchmoz.com/mylan-partnering-2005-2012-report.html>Mylan Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mylan-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Novartis Partnering 2005-2012</title><link>http://www.researchmoz.com/novartis-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/novartis-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/novartis-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Novartis and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/novartis-partnering-2005-2012-report.html>Novartis Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Novartis and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading par <br><br>Original Post <a href=http://www.researchmoz.com/novartis-partnering-2005-2012-report.html>Novartis Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/novartis-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Novo Nordisk Partnering 2005-2012</title><link>http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Novo Nordisk and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading <br><br>Original Post <a href=http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html>Novo Nordisk Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Novo Nordisk and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading <br><br>Original Post <a href=http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html>Novo Nordisk Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/novo-nordisk-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Nycomed Partnering 2005-2012</title><link>http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Nycomed and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html>Nycomed Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Nycomed and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading part <br><br>Original Post <a href=http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html>Nycomed Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/nycomed-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Otsuka Partnering 2005-2012</title><link>http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Otsuka and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html>Otsuka Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Otsuka and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html>Otsuka Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/otsuka-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pfizer Partnering 2005-2012</title><link>http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Pfizer and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html>Pfizer Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Pfizer and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html>Pfizer Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pfizer-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Roche Partnering 2005-2012</title><link>http://www.researchmoz.com/roche-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/roche-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/roche-partnering-2005-2012-report.html</guid><description><![CDATA[r interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability o <br><br>Original Post <a href=http://www.researchmoz.com/roche-partnering-2005-2012-report.html>Roche Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[r interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability o <br><br>Original Post <a href=http://www.researchmoz.com/roche-partnering-2005-2012-report.html>Roche Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/roche-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sanofi Partnering 2005-2012</title><link>http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html</link><comments>http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html#comments</comments><pubDate>Fri, 01 Jun 2012 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html</guid><description><![CDATA[This report provides all the information you require to better understand Sanofi and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html>Sanofi Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This report provides all the information you require to better understand Sanofi and its partnering interests and activities over the past seven years.One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the companys business development objectives.The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partn <br><br>Original Post <a href=http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html>Sanofi Partnering 2005-2012</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sanofi-partnering-2005-2012-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item></channel></rss>